SANTA CLARA, Calif., Jan. 12, 2017 /PRNewswire/ -- Advancements in genomic research, identification of target-specific biomarkers, and the shift toward personalized medicine are driving the adoption of companion diagnostics (CDx) in various therapeutic areas such as oncology, neurology, cardiovascular and gastrointestinal. Therefore, pharmaceutical and biotechnology companies must understand the intellectual property (IP) issues affecting the CDx sector. Companies seeking IP protection for diagnostics in multiple jurisdictions should thoroughly understand the patentability regime in each jurisdiction to formulate most appropriate IP strategies.
"In the CDx market, participants can achieve a competitive edge by building a strong patent portfolio covering major therapeutic areas," said TechVision Senior Consultant Manmohan Singh. "However, patentability criteria for diagnostic methods vary significantly in different countries. Players should also look toward recent legal cases for guidance about the scope of patent-eligible subject matter for diagnostic claims in different jurisdictions."
Companion Diagnostics – A Strategic Review from an IP Perspective is part of Frost & Sullivan's TechVision subscription program. The research highlights opportunities and risks in CDx from a patenting perspective. It provides an overview of key IP issues, recent cases for diagnostics and gene patenting in the United States, and their business impact. It also provides strategic recommendations for formulating an appropriate IP strategy.
Click here for complimentary access to more information on this analysis and to register for a Growth Strategy Dialogue, a free interactive workshop with Frost & Sullivan's thought leaders.
The key IP issues relevant to companion diagnostics are patent eligibility, prosecution, and enforceability in various target markets. The Mayo vs. Prometheus and Association for Molecular Pathology vs. Myriad Genetics case decisions have narrowed the scope of the first screen for patent eligibility. However, claimed material must still meet the criteria of novelty and non-obviousness.
"In the Mayo case, the Court held that diagnostic methods claims were directed towards natural laws and without 'significantly different' claims, such methods were non-patentable," noted Singh. "In the Myriad case, the Supreme Court held that a naturally occurring Deoxyribonucleic Acid (DNA) segment is a product of nature and not patent-eligible merely because it has been isolated, but Complementary DNA (cDNA) is patent eligible because it is not naturally occurring."
Frost & Sullivan's global TechVision practice is focused on innovation, disruption and convergence, and provides a variety of technology-based alerts, newsletters and research services as well as growth consulting services. Its premier offering, the TechVision program, identifies and evaluates the most valuable emerging and disruptive technologies enabling products with near-term potential. A unique feature of the TechVision program is an annual selection of 50 technologies that can generate convergence scenarios, possibly disrupt the innovation landscape, and drive transformational growth. View a summary of our TechVision program by clicking on the following link: http://ifrost.frost.com/TechVision_Demo.
About Frost & Sullivan
Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today's market participants. For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. Contact us: Start the discussion.
Companion Diagnostics – A Strategic Review from an IP Perspective
Corporate Communications – North America
P: +54 (11) 4778 3540
SOURCE Frost & Sullivan